The Globe and Mail reports in its Saturday, May 6, edition that BMO Capital Markets analyst Peter Sklar is holding on to his "outperform" recommendation for Martinrea International. The Globe's David Leeder writes in the Eye On Equities column that Mr. Sklar trimmed his share target back by a loonie to $17. Analysts on average target the shares at $18.88. Mr. Sklar says in a note: "Martinrea reported Q1/23 adjusted EPS of $0.54, below BMO Research/Mean estimate of 62 cents to 59 cents. The underperformance versus our expectations was largely due to disappointing European segment results, which recorded moderate commercial settlements compared to Q4/22 and experienced production volatilities during the quarter. The North American segment delivered positive results on the back of improving volumes, ramp of new programs, and favorable commercial settlements." The Globe reported on Aug. 10 that BMO Capital rated Martinrea "market perform." It was then worth $10.59. The Globe reported on Dec. 24 and March 6 that CIBC World Markets analyst Krista Friesen had rated Martinrea "neutral." It shares were then going for $10.64 and $14.90.